Taylor Scruggs
Pain Medicine · Spanish Fort, ALNPI 1992159578
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,331 of the $5,716 with a category attached, or 75.8%. 29 manufacturers reported payments, led by Medtronic at 43.6% of the total. Reporting peaked in 2022 at $1,800 and has fallen 60.0% since, to $720 in 2025.
Across 181 payments — averaging $31.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Abbott$422
- Curonix LLC$384
- Boston Scientific$367
- AbbVie$333
- SPR Therapeutics, Inc$295
- plus $1K from 23 others
What the payments were for
- Travel & lodging$1,38524%
- Food & beverage$4,33176%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 50 | $2,490 |
| Abbott | 11 | $422 |
| Curonix LLC | 6 | $384 |
| Boston Scientific | 3 | $367 |
| AbbVie | 18 | $333 |
| SPR Therapeutics, Inc | 15 | $295 |
| Collegium Pharmaceutical, Inc. | 13 | $207 |
| Acadia Pharmaceuticals Inc | 8 | $182 |
| Amgen | 10 | $155 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $151 |
| AstraZeneca | 4 | $87 |
| Arbor Pharmaceuticals, Inc. | 5 | $80 |
| Si-bone, Inc. | 2 | $59 |
| Saluda Medical Americas, Inc. | 3 | $57 |
| EMD Serono, Inc. | 3 | $55 |
| Tanabe Pharma America, Inc. | 2 | $40 |
| Neurocrine Biosciences, Inc. | 2 | $38 |
| Scilex Pharmaceuticals Inc. | 2 | $38 |
| Averitas Pharma Inc. | 2 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| Globus Medical | 1 | $32 |
| Lilly USA, LLC | 2 | $32 |
| SK Life Science, Inc. | 1 | $27 |
| Nevro Corp. | 1 | $26 |
| Relievant Medsystems, Inc. | 1 | $25 |
| Vertex | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Merz Pharmaceuticals, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,716 in reported general payments places this provider in the 80th percentile of 77 pain medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine | 302 | $71,653 |
| BelbucaBuprenorphine Hcl | 117 | $63,568 |
| RelistorMethylnaltrexone Bromide | 13 | $29,721 |
| Nucynta ErTapentadol Hcl | 28 | $26,192 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 139 | $24,928 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,087 | $24,485 |
| Xtampza ErOxycodone Myristate | 29 | $20,397 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 666 | $16,484 |
| Lidocaine | 143 | $11,580 |
| MovantikNaloxegol Oxalate | 24 | $10,435 |
| Pregabalin | 467 | $10,346 |
| Gabapentin | 866 | $9,924 |
| NucyntaTapentadol Hcl | 15 | $9,221 |
| ZtlidoLidocaine | 21 | $8,114 |
| SymproicNaldemedine Tosylate | 12 | $6,991 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Nucynta Er, Xtampza Er, Nucynta | $207 | $119,377189 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $151 | $29,72113 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $38 | $8,11421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 77 pain medicine providers in Alabama.
Other pain medicine in Spanish Fort
- Christopher PaulBirmingham$64K
- Michael CosgroveHuntsville$25K
- Ron PitkanenMountain Brk$16K
- Elliott PenningtonDaphne$15K
- James ThackerHuntsville$13K
- Grant StoneMobile$11K
- Hayden HundleyDothan$11K
- Hugh MaddoxAnniston$10K
- Jeremy BarlowVestavia Hills$9K
- Nitin ChhabraHoover$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.